There are currently 979 clinical trials in San Antonio, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Health Science Center at San Antonio, GSK Investigational Site, Pfizer Investigational Site and Methodist Children's Hospital of South Texas. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
NCT06843590
Recruiting
The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/27/2025
Locations: Alkermes Investigational Site, San Antonio, Texas
Conditions: Idiopathic Hypersomnia
Register for Updates
An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure
NCT06859970
Recruiting
The purpose of this early feasibility study is to evaluate the safety and feasibility of the device for percutaneous shunting of the interatrial septum and improvement of heart failure related symptoms. The primary goal is to determine if the device is safe to use. The findings from this study may be used to refine the intended patient population, the design of the device, or develop a subsequent randomized study.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
06/27/2025
Locations: Methodist Healthcare, San Antonio, Texas
Conditions: Heart Failure, Heart Failure NYHA Class III, Heart Failure with Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
Register for Updates
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734
Recruiting
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thromb... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Mays Cancer Center, San Antonio, Texas +1 locations
Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Register for Updates
Fenofibrate for Prevention of DR Worsening
NCT04661358
Recruiting
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the dru... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/26/2025
Locations: Retinal Consultants of San Antonio, San Antonio, Texas
Conditions: Diabetic Retinopathy
Register for Updates
Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM
NCT05145491
Recruiting
Vitrectomy to remove an epiretinal membrane (ERM) is one of the most common procedures performed by retinal surgeons. Patients who present with significant macular changes on optical coherence tomography (OCT) but relatively good vision are often advised to defer surgery until vision declines to 20/40 or worse. However, it is unknown if delaying surgery, which allows the foveal architecture to remain compromised and potentially to deteriorate, results in worse visual acuity outcomes than if surg... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/26/2025
Locations: Retinal Consultants of San Antonio, San Antonio, Texas
Conditions: Epiretinal Membrane
Register for Updates
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Texas Oncology -San Antonio - 1122, San Antonio, Texas
Conditions: Non Small Cell Lung Cancer
Register for Updates
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028
Recruiting
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/26/2025
Locations: Retinal Consultants of Texas, San Antonio, Texas
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates
SGLTi, Hepatic Glucose Production and Ketogenesis
NCT05960656
Recruiting
In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and type 1 diabetes (T1D), and that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. We will conduct five distinct experiments to test this hypothesis in patients with T2D and T1D. MAIN S... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
06/26/2025
Locations: Texas Diabetes Institute/UH, San Antonio, Texas
Conditions: Type 2 Diabetes
Register for Updates
SGLT2i, Hepatic Glucose Production, and SNS
NCT07053293
Recruiting
In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and type 1 diabetes (T1D), and that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. We will conduct five distinct experiments to test this hypothesis in patients with T2D and T1D. Sub-st... Read More
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
06/26/2025
Locations: Texas Diabetes Institute/UH, San Antonio, Texas
Conditions: Type 2 Diabetes
Register for Updates
SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
NCT07053306
Recruiting
To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
06/26/2025
Locations: Texas Diabetes Institute/UH, San Antonio, Texas
Conditions: Type 2 Diabetes
Register for Updates
SGLT2i, Pioglitazone, and Ketone Production in T2D
NCT07053319
Recruiting
To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).
Gender:
ALL
Ages:
Between 30 years and 75 years
Trial Updated:
06/26/2025
Locations: Texas Diabetes Institute/UH, San Antonio, Texas
Conditions: Type 2 Diabetes
Register for Updates
Modifying Adiposity Through Behavioral Strategies to Improve COVID-19 Rehabilitation
NCT05880108
Recruiting
The research in this VA Merit will examine the effects of obesity and Post-COVID Conditions (PCC) on physical functioning, health-related quality of life, and adipose tissue inflammatory and cellular senescence profiles in older Veterans. Further, it will evaluate whether a weight loss intervention, including dietary modification and exercise, in obese Veterans with and without PCC will reduce systemic and adipose tissue inflammation and senescence and promote PCC recovery.
Gender:
ALL
Ages:
80 years and below
Trial Updated:
06/25/2025
Locations: South Texas Health Care System, San Antonio, TX, San Antonio, Texas
Conditions: Post-COVID Conditions, Obesity
Register for Updates